Lipo-C Regulatory Status As of July 2026 , Lipo-C is not FDA-approved
These abnormally expressed thyrocytes function as antigen-presenting cells (APCs) that can present thyroid autoantigens to trigger autoimmune thyroid disease
Users report a range of short-lived side effects including facial flushing, nausea, temporary freckling and darkening of moles, and in some males, spontaneous erections
Iida T, Hayashi N, Yamada T, et al
The difference in mechanism explains why these medications are chosen based on individual treatment goals rather than one being universally better
There appears to be a direct anti-inflammatory effect independent of metabolic changes